| The elevated serum ferritin was one of the risk factors for type 2 diabetes, and soluble transferrin receptor‐to‐ferritin ratio was inversely related to the risk of type 2 diabetes. A systematic review showed that serum transferrin and hepcidin might be directly or indirectly related to the development of diabetes (Journal of Diabetes Investigation)
Since retinopathy occurs at higher HbA1c levels in black people for a given level of average plasma glucose, strategies may be needed to individualize the interpretation of HbA1c measurements (Diabetic Medicine)
There was variation in proportions of the primary care type 2 diabetes population fulfilling inclusion criteria of SGLT‐2i CVOTs. The more stringent the inclusion criteria, the lower the proportion identified in a primary care setting. Prescription rates for SGLT‐2is were low in this national database, and there were demographic disparities in prescribing (Diabetic Medicine)
This review describes the present evidence on diverse pharmacological and therapeutic aspects for various SGLT2 inhibitors, as an attempt to provide useful guidance for optimum application in clinical practice (Diabetes Therapy)
Empagliflozin‐associated changes in conventional CV risk factors in EMPA‐REG OUTCOME appear to explain only a small proportion of the CV and all‐cause death reductions observed. Alternative risk‐reduction mechanisms need to be explored to determine if the observed CV risk changes can be explained by other factors, or possibly by a direct drug‐specific effect (Diabetes, Obesity and Metabolism)
In people with type 2 diabetes and normoalbuminuria, a high-risk score from the urinary proteomic classifier CKD273 was associated with an increased risk of progression to microalbuminuria over a median of 2·5 years, independent of clinical characteristics. However, spironolactone did not prevent progression to microalbuminuria in high-risk patients (The Lancet Diabetes & Endocrinology)
The observed molecular pathways targeted by dapagliflozin and associated with DKD suggest that modifying molecular processes related to energy metabolism, mitochondrial function, and endothelial function may contribute to its renal protective effect (Diabetes, Obesity and Metabolism)
Nocturnal hypoglycemia constitutes nearly one-third of hypoglycemic events in people with T1D. Strict glycemic control and great fluctuation of glucose are potential contributory factors. Daily SMBG profiles and the BGn model could help assess the risk of nocturnal hypoglycemia in T1D, which may support further development of preventive strategies (Diabetes Therapy)
| 